

Reprinted from *WHO Chronicle*, Vol. 21, No. 11, pp. 478-502

INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 18

International Non-Proprietary Names for Pharmaceutical Preparations


In accordance with article 3 of the Procedure for the Selection of Recommended International Non-Proprietary Names for Pharmaceutical Preparations,¹ notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Non-Proprietary Names.

Comments on, or formal objections to, the

proposed names may be forwarded by an person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in the *WHO Chronicle*.

The inclusion of a name in the lists of proposed international non-proprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 18 ²

| Proposed International Non-Proprietary Name (Latin, English) | Chemical Name or Description, Molecular and Graphic Formulae |
|--|---|
| acetergaminum acetergamine | (+)-N-acetyl-9,10-dihydrolysergamine <chem>C14H16N2O</chem> |
| |  |
| acidum acexamicum acexamic acid | 6-acetamidohexanoic acid <chem>C7H13NO3</chem> |
| | <chem>CC(=O)NCCC(CC)C(=O)O</chem> |

¹ See Annex, p. 500.

² Other lists of proposed international non-proprietary names can be found in *Chron. Wild Hlth Org.*, 1953, 7, 299; 1954, 8, 216, 313; 1956, 10, 28; 1957, 11, 231; 1958, 12, 102; *WHO Chronicle*, 1959, 13, 105, 152; 1960, 14, 168, 244; 1961, 15, 314; 1962, 16, 385; 1963, 17, 389; 1964, 18, 433; 1965, 19, 446; 1966, 20, 216; 1967, 21, 70.


Lists of recommended international non-proprietary names were published in *Chron. Wild Hlth Org.*, 1955, 9, 185; *WHO Chronicle*, 1959, 13, 106, 463; 1962, 16, 101; 1965, 19, 165, 206, 249; 1966, 20, 421.

*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


acidum amfonelicum
amfonelic acid

7-benzyl-1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic
acid
 $C_{15}H_{13}N_2O_3$




acidum cromoglicicum
cromoglicic acid

5,5'-(2-hydroxytrimethylenedioxy)bis[4-oxo-4*H*-1-benzopyran-2-
carboxylic acid]
 $C_{23}H_{16}O_{11}$




acidum cyclobutoicum
cyclobutoic acid

β -hydroxy- β -methylcyclohexaneproponic acid
 $C_{11}H_{18}O_3$




acidum iocetamicum
iocetamic acid

N-acetyl-*N*-(3-amino-2,4,6-triiodophenyl)-2-methyl- β -alanine
 $C_{12}H_{13}I_3N_2O_3$



alipamidum
alipamide

4-chloro-3-sulfamoylbenzoic acid 2,2-dimethylhydrazide
 $C_{11}H_{12}ClN_2O_3S$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


amiloridum
amiloride

N-amidino-3,5-diamino-6-chloropyrazinecarboxamide
 $C_4H_4ClN_5O$




azaperonum
azaperone

4'-fluoro-4-[4-(2-pyridyl)-1-piperazinyl]butyrophenone
 $C_{18}H_{22}FN_2O$




azatadinum
azatadine

6,11-dihydro-11-(1-methyl-4-piperidylidene)-5*H*-benzo[5,6]cyclohepta-
[1,2-*b*]pyridine
 $C_{20}H_{22}N_2$




benazolinum
benazoline

2-[(2-methylbenzo[*b*]thien-3-yl)methyl]-2-imidazoline
 $C_{15}H_{11}N_2S$



bensalanum
bensalan

3,5-dibromo-*N*-(*p*-bromobenzyl)salicylamide
 $C_{14}H_{10}Br_3NO_2$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


bentipiminum
bentipimine

1-[2-[(*o*-chloro- α -phenylbenzyl)thio]ethyl]-4-(*o*-methylbenzyl)pipe-
razine
 $C_{27}H_{31}ClN_2S$




benzathini benzylpenicillinum
benzathine benzylpenicillin

N,N'-dibenzylethylenediamine salt of benzylpenicillin
 $C_{18}H_{26}N_2 \cdot 2C_{18}H_{18}N_2O_4S$




benzoxiquinum
benzoxiquine

8-quinolinol benzoate (ester)
 $C_{18}H_{11}NO_2$




bisoxatinum
bisoxatin

2,2-bis(*p*-hydroxyphenyl)-2*H*-1,4-benzoxazin-3(4*H*)-one
 $C_{20}H_{15}NO_4$



boxidinum
boxidine

1-[2-[[4'-(trifluoromethyl)-4-biphenyl]oxy]ethyl]pyrrolidine
 $C_{18}H_{20}F_3NO$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*

brocresinum
brocresine

α -(aminooxy)-6-bromo-*m*-cresol
 $C_7H_7BrNO_2$




bromelaina
bromelains

a concentrate of proteolytic enzymes derived from *Ananas comosus* Merr.


captaminum
captamine

2-(dimethylamino)ethanethiol
 $C_4H_{11}NS$



cefalexinum
cefalexin

D-7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
 $C_{17}H_{17}N_2O_4S$




cellacefatum
cellacefate

a mixed acetate and hydrogen phthalate ester of cellulose (about 50 per cent. of the hydroxyl groups are acetylated and about 25 per cent. are esterified with one of the carboxyl groups of phthalic acid)


ciclactatum
ciclactate

3,3,5-trimethylcyclohexyl lactate
 $C_{12}H_{22}O_3$



ciclofenazinum
ciclofenazine

10-[3-(4-cyclopropyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine
 $C_{33}H_{28}F_3N_3S$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


cinperenum
cinperene

2-(1-cinnamyl-4-piperidyl)-2-phenylglutarimide
 $C_{23}H_{28}N_2O_2$




ciproximidum
ciproximide

1-(*p*-chlorophenyl)-1,2-cyclopropanedicarboximide
 $C_{11}H_8ClNO_2$




cisclolifenum
cisclolifene

2-[*p*-(2-chloro-*cis*-1,2-diphenylvinyl)phenoxy]triethylamine
 $C_{28}H_{28}ClNO$




clobenzorexum
clobenzorex

(+)-*N*-(*o*-chlorobenzyl)- α -methylphenethylamine
 $C_{14}H_{17}ClN$



clofluperolum
clofluperol

4-[4-(*p*-chloro-*m*-trifluoromethylphenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone
 $C_{22}H_{22}ClF_4NO_2$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


clonazolinum
clonazoline

2-(4-chloro-1-naphthylmethyl)-2-imidazoline
 $C_{14}H_{13}ClN_2$




cloperastinum
cloperastine

1-[2-[(p-chloro- α -phenylbenzyl)oxy]ethyl]piperidine
 $C_{20}H_{24}ClNO$




decitropnum
decitropine

3 α -(5H-dibenzo[a,d]cyclohepten-5-yloxy)tropane
 $C_{23}H_{25}NO$




diaveridinum
diaveridine

2,4-diamino-5-(3',4'-dimethoxybenzyl)pyrimidine
 $C_{13}H_{14}N_4O_2$



diflucortolonum
diflucortolone

6 α ,9-difluoro-11 β ,21-dihydroxy-16 α -methylpregna-1,4-diene-3,20-dione
 $C_{22}H_{28}F_2O_4$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


diniprophyllinum
diniprophylline

7-(2,3-dihydroxypropyl)theophylline bis(nicotinate ester)
 $C_{22}H_{26}N_6O_8$




dopaminum
dopamine

4-(2-aminoethyl)pyrocatechol
 $C_8H_{11}NO_2$




dropropizinum
dropropizine

3-(4-phenyl-1-piperazinyl)-1,2-propanediol
 $C_{15}H_{20}N_2O_2$




emepronii bromidum
emepronium bromide

ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide
 $C_{20}H_{28}BrN$



etamocyclinum
etamocycline

N,N-(ethylenebis[(methylimino)methylene])bis[4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide]
 $C_{50}H_{50}N_6O_{16}$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


etilefrinum
etilefrine

α -[(ethylamino)methyl]-*m*-hydroxybenzyl alcohol
 $C_{10}H_{15}NO_2$




etodroxizinum
etodroxizine

2-[2-[2-[4-(*p*-chloro- α -phenylbenzyl)-1-piperazinyl]ethoxy]ethoxy]ethanol
 $C_{23}H_{31}ClN_2O_3$




etofuradinum
etofuradine

N-(benzofuran-2-ylmethyl)-*N*-2-pyridyl-*N'*,*N'*-dimethylethylenediamine
 $C_{18}H_{21}N_3O$




etonamum
etonam

ethyl 1-(1,2,3,4-tetrahydro-1-naphthyl)imidazole-5-carboxylate
 $C_{17}H_{19}N_2O_2$



fantridonum
fantridone

5-[3-(dimethylamino)propyl]-6(5*H*)-phenanthridinone
 $C_{17}H_{21}N_2O$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


fenalamidum
fenalamide

ethyl *N*-[2-(diethylamino)ethyl]-2-ethyl-2-phenylmalonamate
 $C_{19}H_{26}N_2O_3$




fencloninum
fenclonine

3-(*p*-chlorophenyl)alanine
 $C_8H_9ClNO_2$




fenestrelum
fenestrel

5-ethyl-6-methyl-4-phenyl-3-cyclohexene-1-carboxylic acid
 $C_{17}H_{20}O_2$




fluprofenum
fluprofen

2-(3'-fluoro-4-biphenyl)propionic acid
 $C_{15}H_{13}FO_2$




fomocainum
fomocaine

1-[3-[4-(phenoxy)methyl]phenyl]propyl)morpholine
 $C_{20}H_{25}NO_2$



formocortalum
formocortal

3-(2-chloroethoxy)-9-fluoro-11 β ,16 α ,17,21-tetrahydroxy-20-oxo-3,5-pregnadiene-6-carboxaldehyde cyclic 16,17-acetal with acetone 21-acetate
 $C_{27}H_{41}ClFO_8$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


fubregonii iodidum
fubregonium iodide

diethyl(3-hydroxybutyl)methylammonium iodide 5-bromo-2-furoate
 $C_{14}H_{28}BrINO_3$




fursalanum
fursalan

3,5-dibromo-*N*-(tetrahydrofurfuryl)salicylamide
 $C_{12}H_{13}Br_2NO_3$




glibenclamidum
glibenclamide

1-[4-[2-(5-chloro-2-methoxybenzamido)ethyl]phenylsulfonyl]-3-cyclohexylurea
 $C_{23}H_{28}ClN_3O_3S$



guancidinum
guancidine

1-cyano-3-*tert*-pentylguanidine
 $C_7H_{11}N_4$




hypromellosum
hypromellose

a mixed methyl and hydroxypropyl ether of cellulose (about 4 to 7 per cent. hydroxypropyl groups and 20 to 30 per cent. methoxyl groups)

imiclopazinum
imiclopazine

1-(2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazinyl]ethyl)-3-methyl-2-imidazolidinone
 $C_{23}H_{22}ClN_5OS$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


leniquinsinum
leniquinsin

6,7-dimethoxy-4-(veratrylideneamino)quinoline
 $C_{18}H_{20}N_2O_4$




levometiomeprazinum
levometiomeprazine

(-)-10-[3-(dimethylamino)-2-methylpropyl]-2-(methylthio)
phenothiazine
 $C_{17}H_{21}N_2S_2$




mecarbinatum
mecarbinat

ethyl 5-hydroxy-1,2-dimethylindole-3-carboxylate
 $C_{13}H_{15}NO_3$




metergolinum
metergoline

(+)-N-(carboxy)-1-methyl-9,10-dihydrolysergamine
benzyl ester
 $C_{23}H_{29}N_3O_2$



minepentatum
minepentate

2-[2-(dimethylamino)ethoxy]ethyl 1-phenylcyclopentanecarboxylate
 $C_{17}H_{27}NO_3$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


mitoclominum
mitoclomine

N,N-bis(2-chloroethyl)-4-methoxy-3-methyl-1-naphthylamine
 $C_{11}H_{13}Cl_2NO$




molindonum
molindone

3-ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5*H*)-one
 $C_{14}H_{18}N_2O_2$




moxicoumonum
moxicoumone

4-methyl-5,7-bis(2-morpholinoethoxy)coumarin
 $C_{22}H_{26}N_2O_6$




naftidrofurylum
naftidrofuryl

2-(diethylamino)ethyl tetrahydro- α -(1-naphthylmethyl)-2-furanpropionate ester
 $C_{21}H_{29}NO_4$



natrii radioitalamas (^{125}I)
sodium radioitalamate (^{125}I)

sodium 5-acetamido-*ar,ar*-diiodo-*ar, ar*-iodo- ^{125}I -*N*-methylisophthalamate
 $C_{11}H_{11}I_3N_2NaO_4$




*Proposed International
Non-Proprietary Name
(Latin, English)*

natrii radioitalamas (¹³¹I)
sodium radioitalamate (¹³¹I)


*Chemical Name or Description,
Molecular and Graphic Formulae*

sodium 5-acetamido-*ar,ar*-diiodo-*ar*-iodo-¹³¹I-*N*-methylisophthalamate
C₁₅H₁₃N₂NaO₄




nifurimidum
nifurimide

(±)-4-methyl-1-[(5-nitrofurfurylidene)amino]-2-imidazolidinone
C₇H₁₀N₂O₄




nifurquinazolum
nifurquinazol

2,2'-[[2-(5-nitro-2-furyl)-4-quinazolinyl]imino]diethanol
C₁₈H₁₆N₂O₅




nonoxinolum 4
nonoxinol 4

2-[2-[2-[2-(*p*-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethanol
C₂₂H₄₀O₅




nonoxinolum 15
nonoxinol 15





44-(*p*-nonylphenoxy)-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradeca-
oxatetratetracontan-1-ol
C₆₅H₁₀₄O₁₄



nonoxinolum 30
nonoxinol 30

89-(*p*-nonylphenoxy)-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,-
57,60,63,66,69,72,75,78,81,84,87-nonacosaoxanonaoctacontan-1-ol
C₁₇₅H₂₈₄O₃₁




| Proposed International Non-Proprietary Name (Latin, English) | Chemical Name or Description, Molecular and Graphic Formulae |
|--|--|
| norgestrienonum norgestrienone | <p>17-hydroxy-19-nor-17α-pregna-4,9,11-trien-20-yn-3-one C₂₂H₃₂O₂</p>  |
| norleusactidum norleusactide | <p>D-seryl-L-tyrosyl-L-seryl-L-norieucyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-propyl-L-valyl-glycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-arganyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-prolyl-L-valinamide C₁₄₂H₂₂₁N₁₂O₂₁</p> <p>H - Ser - Tyr - Ser - Nle - Glu - His - Phe - Arg Try - Gly - Lys - Pro - Val - Gly - Lys - Lys Arg - Arg - Pro - Val - Lys - Val - Tyr - Pro Val - NH₂</p> |
| octabenzonum octabenzone | <p>2-hydroxy-4-(octyloxy)benzophenone C₂₁H₁₈O₂</p>  |
| octaverinum olivaverine | <p>6,7-dimethoxy-1-(3,4,5-triethoxyphenyl)isoquinoline C₂₂H₂₇NO₅</p>  |
| olivomycinum olivomycin | <p>an antibiotic obtained from cultures of <i>Actinomyces olivoreliculi</i>, or the same substance obtained by any other means</p> |
| oxipurinolum oxipurinol | <p>1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine-4,6-diol C₅H₄N₄O₂</p>  |

*Proposed International
Non-Proprietary Name
(Latin, English)*

oxitefonii bromidum
oxitefonium bromide


*Chemical Name or Description,
Molecular and Graphic Formulae*

diethyl(2-hydroxyethyl)methylammonium bromide α -phenyl-2-thio-
pheneglycolate
 $C_{15}H_{21}BrNO_3S$




parapropamolum
parapropamol

4'-hydroxypropionanilid
 $C_9H_{11}NO_2$




pentagastrinum
pentagastrin

N-t-butyloxycarbonyl- β -alanyl-L-tryptophyl-L-tryptophyl-L-methio-
nyl-L-aspartyl-L-phenylalanine amide
 $C_{57}H_{71}N_7O_8S$



perimetazinum
perimetazine

1-[3-(2-methoxyphenothiazin-10-yl)-2-methylpropyl]-4-piperidinol
 $C_{22}H_{23}N_2O_2S$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


picodralazinum
picodralazine

1-hydrazino-4-(4-pyridylmethyl)phthalazine
 $C_{14}H_{13}N_5$




pimozidum
pimozide

1-{1-[4,4-bis(*p*-fluorophenyl)butyl]-4-piperidyl}-2-benzimidazolinone
 $C_{23}H_{23}F_2N_3O$




pinoxepinum
pinoxepin

c s-4-[3-(2-chlorodibenz[*b,e*]oxepin-11(6*H*)-ylidene)propyl]-1-piperazineethanol
 $C_{23}H_{24}ClN_2O_2$



piridoxilatum
piridoxilate

[(5-hydroxy-4-hydroxymethyl-6-methyl-3-pyridyl)methoxy]-glycolic acid
 $C_{10}H_{13}NO_6$



polisaponinum
polisaponin


a mixture of all the steroid saponins isolated from the rhizome of
Dioscorea polystachya

*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*

quatacaïnium
quatacaine

2-methyl-2-(propylamino)-o-propionotoluidide
 $C_{14}H_{22}N_2O$




radiocesii chloridum (^{137}Cs)
radiocesium chloride (^{137}Cs)

cesium chloride
 $^{137}\text{CsCl}$

retinolum
retinol

3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-
traen-1-ol
 $C_{26}H_{44}O$




ribaminolum
ribaminol

2-diethylammonium ethanol ribonucleate


ronidazolium
ronidazole

(1-methyl-5-nitroimidazol-2-yl)methyl carbamate
 $C_6H_7N_3O_4$




silandronum
silandrone

17β-(trimethylsiloxy)androst-4-en-3-one
 $C_{28}H_{48}O_2\text{Si}$



sotalolum
sotalol

4'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide
 $C_{17}H_{25}N_2O_3S$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulas*


stanozololum
stanozolol

17 β -hydroxy-17 α -methylandrostando[3,2-*c*]pyrazole
C₂₁H₃₂N₂O




sulfapyrazolum
sulfapyrazole

*N*¹-(3-methyl-1-phenylpyrazol-5-yl)sulfanilamide
C₁₁H₁₁N₃O₂S




sulforidazinum
sulforidazine

10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfonylphenothiazine
C₂₁H₂₄N₂O₂S₂




sulpiridum
sulpiride

N'-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfamoylbenzamide
C₁₅H₂₃N₃O₃S



sultroponium
sultroponium

8-(3-sulfopropyl)atropinium hydroxide inner salt
C₂₀H₂₇NO₃S



sutillaina
sutillains


proteolytic enzymes derived from *Bacillus subtilis*

*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*

talastinum
talastine

2-[2-(dimethylamino)ethyl]-4-benzyl-1(2*H*)phthalazinone
 $C_{17}H_{21}N_3O$




tetracosactidum
tetracosactide

L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-prolyl-L-valyl-glycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-proline
 $C_{133}H_{210}N_{16}O_{31}S$

H - Ser - Tyr - Ser - Met - Glu - His - Phe - Arg - Try - Gly -
Lys - Pro - Val - Gly - Lys - Lys - Arg - Arg - Pro - Val - Lys -
Val - Tyr - Pro - OH


tetradonii bromidum
tetradonium bromide

trimethyltetradecylammonium bromide
 $C_{17}H_{35}BrN$




tibrofanum
tibrofan

4,4',5-tribromo-2-thiophenecarboxanilide
 $C_{11}H_4Br_3NOS$



tiosalanum
tiosalan

3,4',5-tribromo-2-mercaptobenzanilide
 $C_{11}H_4Br_3NOS$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


tixadilum
tixadil

N-(α -methylphenethyl)thioxanthene-9-ethylamine
 $C_{21}H_{23}NS$



transclomifenum
transclomifene


2-[*p*-(2-chloro-*trans*-1,2-diphenylvinyl)phenoxy]triethylamine
 $C_{21}H_{23}ClNO$



$(C_2H_5)_2N-CH_2-CH_2-O$


tropodifenum
tropodifene

tropine 3-(*p*-hydroxyphenyl-2-phenylpropionate (ester) acetate
(ester)
 $C_{23}H_{29}NO_4$




vanitilidum
vanitilide

4-(thiovanilloyl)morpholine
 $C_{13}H_{15}NO_2S$



zolaminum
zolamine

2-[(dimethylamino)ethyl](*p*-methoxybenzyl)aminothiazole
 $C_{15}H_{21}N_3OS$



NAMES FOR RADICALS AND GROUPS

Some preparations for which a proposed international non-proprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic

chemical nomenclature. The following shorter non-proprietary names for some such radicals and groups have been devised or selected, and they are suggested for use with proposed international non-proprietary names.

| | |
|--|---------------|
| methylphenylmethylene | acetofenide |
| isopropylidene ether of a dihydric alcohol | acetonide |
| 4,4'-diaminostilbene-2,2'-disulfonate | amsonate |
| camphorsulfonate | camsilate |
| cyclopentanepropionate | cipionate |
| <i>p</i> -chlorbenzenesulfonate | closilate |
| 1,2-ethanedisulfonate | edisilate |
| 4,4'-methylenebis(3-hydroxy-2-naphthoate) | embonate |
| heptanoate | enantate |
| ethanesulfonate | esilate |
| glucoheptonate | gluceptate |
| <i>o</i> -(4-hydroxybenzoyl)benzoate | hibenzate |
| 2-hydroxyethanesulfonate | isetionate |
| <i>N</i> -methylglucamine | meglumine |
| methanesulfonate | mesilate |
| methylsulfate | metilsulfate |
| 1,5-naphthalenedisulfonate | napadisillate |
| 2-naphthalenesulfonate | napsilate |
| trimethylacetate | pivalate |
| stearoyl-glycolate | steaglate |
| 8-chlorotheophyllinate | teoclote |
| <i>p</i> -toluenesulfonate | tosilate |
| 2,4,5-trichlorophenolate | triclofenate |

CORRIGENDA

Vol. 16, No. 10

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 12

p. 390: *delete*

meractinomycinum
meractinomycin

insert

dactinomycinum
dactinomycin

Vol. 17, No. 10

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 13

p. 398: *delete*

virgimycinum
virgimycin

insert

virginiamycinum
virginiamycin

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 17

| | |
|----------------------|------------------------|
| p. 71: <i>delete</i> | <i>insert</i> |
| antridonit chloridum | isometamidii chloridum |
| antridonium chloride | isometamidium chloride |
| <i>delete</i> | <i>insert</i> |
| cinnopropazonum | azapropazonum |
| cinnopropazone | azapropazone |
| p. 76: <i>delete</i> | <i>insert</i> |
| nonoxynolum | nonoxinolum 9 |
| nonoxynol | nonoxinol 9 |

Annex

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS *

The following procedure shall be followed by the World Health Organization in the selection of recommended international non-proprietary names for pharmaceutical preparations, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international non-proprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Non-proprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical preparation shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international non-proprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*¹ and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

(i) set forth the name under consideration;

(ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;

(iii) identify the substance for which a name is being considered;

(iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

(v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3).

¹ The title of this publication was changed to *WHO Chronicle* in January 1959.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

A. Such objection shall:

(i) identify the person objecting;

(ii) state his interest in the name;

(iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international non-proprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international non-proprietary name.

8. In forwarding a recommended international non-proprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the non-proprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS *

1. Names should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names already in common use.

2. The name for a substance belonging to a group of pharmacologically related substances should show this relationship. The name should be free from any anatomical, physiological, pathological or therapeutic suggestion.

The above primary principles are to be implemented by utilization of the following secondary principles.

3. In devising the name of the first substance in a new pharmacological group (the parent substance), consideration should be given to the possibility of devising suitable names for related substances belonging to the new group.

4. Syllables such as "methylhydro", "methoxy", and "chlor" should preferably be abbreviated (to "medro", "meto", "clo", etc.).

5. In the naming of substances which are acids, existing names generally used in chemistry which include the word "acidum" ("acid") should be used, if the name is adequate for practical use in therapy and pharmacy. In other circumstances, the substance should be named by a single word and not by a name which includes the word "acid". Where the word "acid" is not used in the name, as is customary in the penicillin series, a salt should preferably be named without modification of the parent acid name, e.g., "oxacillin" and "oxacillin sodium".

6. Names for substances which are used as salts should in general apply to the active base (or the active acid). Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid (or the inactive base). Exceptions may have to be made for those cases in which pharmacological activity may reside in both parts of the salt or ester.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

* Text adopted by the Executive Board of WHO in resolution EB37.R9 (*Off. Rec. Wld Hlth Org.*, 1966, 148, 9).

7. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.
8. To facilitate translation and pronunciation "f" should preferably be used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y".
9. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.
10. Group relationship in names (see item 2) should preferably be shown by using common syllables in the following list. Where a syllable or a group of syllables is shown without any hyphens it may be used anywhere in the name. The syllable, or group of syllables, should, if possible, be used only for such substances.
- Subsidiary group relationships should be shown by devising names which show similarities to and are analogous with a previously named substance, the parent substance.
- At the end of the list are general chemical syllables. Should they come into conflict with other suggested syllables, the suffix conveying the best information should be used.

| <i>Latin</i> | <i>English</i> | <i>French</i> | |
|--------------|----------------|---------------|---|
| -andr- | -andr- | -andr- | } steroids, androgenic |
| or -stan- | or -stan- | or -stan- | |
| or -ster- | or -ster- | or -ster- | |
| -apol- | -apol- | -apol- | polysulfonic anticoagulants |
| -arolum | -arol | -arol | anticoagulants |
| -bamatum | -bamate | -bamate | tranquillizers of the propanediol and pentanediol series |
| barb | barb | barb | barbituric acids |
| bol | bol | bol | anabolic steroids |
| -cainum | -caine | -caine | local anaesthetics |
| cef- | cef- | céf- | antibiotics with cephalosporanic acid nucleus |
| -cillinum | -cillin | -cilline | penicillins: derivatives of carboxy-6-amino-penicillanic acid |
| -cort- | -cort- | -cort- | steroids, glucocorticoids and mineralocorticoids, other than prednisolone derivatives |
| -crinum | -crine | -crine | acridine derivatives, antimicrobial |
| -curonium | -curonium | -curonium | curare-like drugs |
| -cyclinum | -cycline | -cycline | antibiotics, tetracycline derivatives |
| -dionum | -dione | -dione | antiepileptics derived from oxazolidinedione |
| -estr- | -estr- | -estr- | estrogenic drugs |
| -gest- | -gest- | -gest- | steroids, progestative |
| gli- | gli- | gli- | sulfonamide oral antidiabetics |
| io- | io- | io- | iodine-containing contrast media |
| -mer- | -mer- | -mer- | mercury-containing drugs, antimicrobial or diuretic |
| -mito- | -mito- | -mito- | nucleotoxic, antineoplastic agents |
| -moxinum | -moxine | -moxine | monoamine oxidase inhibitors |
| -mycinum | -mycin- | -mycine | antibiotics, produced by <i>Streptomyces</i> strains |
| nifur- | nifur- | nifur- | 5-nitrofur derivatives |
| -orexum | -orex | -orex | anorexigenic agents |
| -praminum | -pramine | -pramine | dibenzazepine, compounds of the imipramine type |
| -quinum | -quine | -quine | quinoline derivatives |
| -serpinum | -serpine | -serpine | derivatives of <i>Rauwolfia</i> alkaloids |
| -stigminum | -stigmine | -stigmine | anticholinesterases |
| sulfa- | sulfa- | sulfa- | sulfonamides, used as antimicrobials |
| -tizidum | -tizide | -tizide | diuretics which are thiazide derivatives |
| -toinum | -toine | -toine | antiepileptics which are hydantoin derivatives |
| -verinum | -verine | -verine | spasmolytics with a papaverine-like action |
| -inum | -ine | -ine | alkaloids and organic bases |
| -onum | -one | -one | ketones |
| -onium | -onium | -onium | quaternary amines |